IQ-AI

The story of IQ-AI, now known as Imaging Biometrics, is one of strategic evolution. It began as Flying Brands Limited, a company that shifted its focus to medical technology. In 2017, the company made its first key acquisition, Stone Checker Software Limited, which developed technology to analyze kidney stones. This was the initial step towards building a portfolio in medical imaging diagnostics. The following year, in March 2018, a more significant acquisition occurred: the purchase of Imaging Biometrics, LLC (IB), a Wisconsin-based healthcare imaging software company. This acquisition was pivotal, bringing in a strong portfolio of neuroimaging products and setting the company's future direction. This strategic shift was solidified in October 2018 when Flying Brands officially changed its name to IQ-AI Limited, signaling a clear commitment to applying artificial intelligence in medical imaging. The company, led by CEO Trevor Brown, focused its resources on the newly acquired neuroimaging technologies. This led to a strategic decision in late 2019 to seek a buyer for the StoneChecker business to concentrate on the neuroimaging field. However, after seeing continued interest and potential for AI integration, the company reversed this decision in late 2020, retaining StoneChecker in its portfolio. Imaging Biometrics was originally co-founded by Michael Schmainda and Dr. Kathleen Schmainda, PhD, in 2007. The company is publicly traded on the London Stock Exchange. In May 2025, to better align the parent company's name with its core operational subsidiary, IQ-AI Limited announced a name change to Imaging Biometrics Ltd.